Management of infection in cancer patients: Studies of the EORTC International Antimicrobial Therapy Group (IATG)

European Journal of Cancer

Volumn 38, Issue SUPPL. 4, 2002, Pages 82-87

  Viscoli, C ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Cancer; Clinical trial; Fever; Infection; Neutropenia

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; CLAVULANIC ACID; GLYCOPEPTIDE; MOXIFLOXACIN; PENICILLIN G; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL INFECTION; BLOOD DISEASE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RESEARCH; CARCINOMA; CLINICAL TRIAL; DRUG SAFETY; FEBRILE NEUTROPENIA; FEVER; HEALTH CARE ORGANIZATION; HUMAN; MORBIDITY; PRIORITY JOURNAL; PUBLICATION; RISK;

EID: 0036181802     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0959-8049(01)00461-0     Document Type: Article

References (25)

1. Infection in patients with acute leukemia and lymphoma
2. Planned progressive antimicrobial therapy in neutropenic patients
3. Gram-negative bacteraemia II. Clinical, laboratory and therapeutic observations
4. Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer
5. Combination of amikacin and carbenicillin with or without cefazolin as empirical treatment of febrile neutropenic patients
6. Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients
7. Ceftazidime combined with a short or long course of amikacin for empirical therapy of Gram-negative bacteremia in cancer patients with granulocytopenia
8. Gram-positive bacteraemia in granulocytopenic cancer patients
9. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients
10. Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors
11. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia
12. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer
13. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empirical therapy for fever in granulocytopenic patients with cancer
14. Oral versus intravenous empirical therapy for fever in cancer patients with an expected short duration of granulocytopenia
15. Trimethoprim-Sulfamethoxazole in the prevention of infection in neutropenic patients
16. Reduction of fever and streptococcal bacteremia in granulocytopenic patients with cancer
17. Empiric antifungal therapy in febrile granulocytopenic patients
18. Factors associated with bacteremia in febrile granulocytopenic cancer patients
19. A comparison of outcome from febrile neutropenic episodes in children compared with adults: Results from four EORTC studies
20. Association between antifungal prophylaxis and rate of documented bacteremia in febrile neutropenic cancer patients
21. Empiric antimicrobial therapy for febrile, granulocytopenic cancer patients: Lesson from 4 EORTC trials
22. An approach to the design and implementation of clinical trials of empirical antibiotic therapy in febrile and neutropenic cancer patients
23. An EORTC-IATG double-blind trial of vancomycin (Van) versus placebo (Pla) for persistent fever in neutropenic cancer patients (NCP) given piperacillin/tazobactam (PT) monotherapy
24. The Multinational Association for Supportive Care in Cancer Risk Index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients
25. The design, analysis and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient